Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NLS Pharmaceutics Ltd. - Ordinary Shares (NQ:NLSP)

0.7620 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NLS Pharmaceutics Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
- Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies - Product sales through the... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale
 
Via Benzinga
80 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares gained 86.7% to close at $0.5150 on Wednesday after the company announced FDA clearance of its IND for SON-... 
Via Benzinga
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
- Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trial - Safety and... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March
ZURICH, SWITZERLAND / ACCESSWIRE / February 25, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
25 Stocks Moving in Monday's Pre-Market Session
Gainers Motus GI Holdings, Inc. (NASDAQ: MOTS) rose 52.8% to $0.65 in pre-market trading after declining 6% on Friday. TC BioPharm (Holdings) plc (NASDAQ: TCBP)... 
Via Benzinga
NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference
ZURICH, SWITZERLAND / ACCESSWIRE / February 11, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
47 Biggest Movers From Yesterday
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH... 
Via Benzinga
Why Are NLS Pharmaceutics Shares Trading Higher During Premarket Monday?
NLS Pharmaceutics Ltd (NASDAQ: NLSP) shares are trading higher after the Company announced to present interim topline data from its Phase 2a trial evaluating its lead product candidate, Quilience... 
Via Benzinga
NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022
- Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled - 21 clinical sites in the United States actively enrolling patients - Nearly 90% of patients completing... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
58 Biggest Movers From Yesterday
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-... 
Via Benzinga
33 Stocks Moving In Thursday's Mid-Day Session
Gainers Eargo, Inc. (NASDAQ: EAR) shares jumped 50.8% to $6.88 after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! Let's start off the day right with a look into some of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
23 Stocks Moving in Thursday's Pre-Market Session
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 54.3% to $0.9490 in pre-market trading after declining more than 11% on Wednesday. Alterity Therapeutics Limited... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! It's time for another busy day of trading with a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
45 Biggest Movers From Yesterday
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced... 
Via Benzinga
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
- Key patent now granted in major markets including the U.S., Europe, Canada & South Korea - Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
18 Stocks Moving in Monday's Pre-Market Session
Gainers Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 41.6% to $3.13 in pre-market trading after gaining around 8% on Friday. Armstrong Flooring, Inc. (NYSE: AFI... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! We're starting off another busy week with a look at the biggest pre-market stock movers for Monday! 
Via InvestorPlace
61 Biggest Movers From Yesterday
Gainers Jowell Global Ltd. (NASDAQ: JWEL) jumped 25.5% to close at $13.36. Jowell Global recently announced a collaboration with Unilever's Uni-Excubator. Information... 
Via Benzinga
40 Stocks Moving In Thursday's Mid-Day Session
Gainers Biofrontera Inc. (NASDAQ: BFRI) surged 39% to $6.02. Biofrontera announced Notice of Allowance for U.S. patent titled 'Illumination for Photodynamic Therapy.'... 
Via Benzinga
Topics Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday. Digital World Acquisition Corp. (NASDAQ: DWAC)... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, traders! We're starting off the day right with a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's... 
Via Benzinga
Topics Intellectual Property
23 Stocks Moving in Wednesday's Pre-Market Session
Gainers Skylight Health Group Inc. (NASDAQ: SLHG) rose 55.3% to $2.05 in pre-market trading after dipping around 10% on Tuesday. Skylight Health Group, last month, posted a... 
Via Benzinga
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.